// App-Quantinova.ai

140 : A risk prediction score based on magnetic resonance cholangiopancreatography (MRCP) accurately predicts disease progression in patients with primary sclerosing cholangitis (PSC)

Researchers

Presenter

  • Andrew J. Muir

Principal Investigators

  • Elmira Hassanzadeh

  • V. Anik Sahni

  • Nisha Sainani

  • Dora Ding

  • Catherine Jia

  • Bryan J. McColgan

  • Chuhan Chung

  • Robert P. Myers

  • Mani Subramanian

  • John G. McHutchison

  • Zachary D. Goodman

  • BertusEksteen

  • MichaelP. Manns

  • Roger W. Chapman

  • Christopher L. Bowlus

  • Cynthia Levy

  • Clare Tempany-Afdhal

Medical Centers

  • Duke Clinical Research Institute, Durham, NC

  • Brigham and Woma-s Hospital, Department of Pathology, Harvard Medical School, Boston, MA

  • Gilead Sciences, Inc., Foster City, CA

  • Inova Fairfax Hospital, Falls Church, VA

  • University of Calgary, Calgary, AB, Canada

  • Hannover Medical School, Hannover, Germany

  • Oxford University, Oxford, United Kingdom

  • University of California, San Francisco, CA

  • University of Miami, Miami, FL

Locations

  • United States

  • Canada

  • Germany

  • United Kingdom

Companies

  • Gilead Sciences, Inc

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Gastroenterology (GU)

Disease

  • Primary sclerosing cholangitis

  • Ascending cholangitis

  • Portal Hypertension

  • Advanced biliary tract carcinoma

  • Hypertension

Biomarkers

  • N/A

Drug/Treatment

  • Simtuzumab

Outcome

  • N/A

Study Design

  • Placebo Control

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved